Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Treasury Shares (2016 - 2025)

Vistagen Therapeutics' Treasury Shares history spans 11 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Treasury Shares changed 0.0% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, changed 0.0%, while the annual FY2025 figure was $4.0 million, 0.0% changed from the prior year.
  • Treasury Shares for Q4 2025 was $4522.0 at Vistagen Therapeutics, roughly flat from $4522.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $135665.0 in Q1 2021 and bottomed at $4522.0 in Q2 2023.
  • The 4-year median for Treasury Shares is $4522.0 (2023), against an average of $41991.4.
  • The largest annual shift saw Treasury Shares changed 0.0% in 2021 before it fell 0.0% in 2024.
  • A 4-year view of Treasury Shares shows it stood at $4.0 million in 2021, then changed by 0.0% to $4.0 million in 2023, then fell by 0.0% to $4.0 million in 2024, then changed by 0.0% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Treasury Shares are $4.0 million (Q4 2025), $4.0 million (Q3 2025), and $4.0 million (Q2 2025).